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Abstract
Aims: Roles of glucagon-like peptide-1 (GLP-1) in extra-pancreatic tissues remain unclear. The aim of this study was to
examine determinants of GLP-1 secretory function and possible contribution of GLP-1 to blood pressure (BP) regulation.
Methods and Results: We recruited 128 subjects who received annual examinations and 75g-oral glucose tolerance tests
(OGTT) in the Tanno-Sobetsu cohort. Subjects on regular medications for cardiovascular and/or metabolic diseases were
excluded, and data for the remaining 103 subjects were used for the univariate and multivariate analyses. Age, plasma
glucose (PG), hemoglobin A1c (HbA1c), plasma insulin, and serum lipids were not selected as independent determinants of
fasting GLP-1 level by multiple linear regression analysis. However, age and female sex were selected as independent
positive determinants of the area under the curve of GLP-1 level during OGTT (AUCGLP-1), an index of GLP-1 secretory
function. Multiple linear regression analysis indicated that AUCGLP-1 was an independent negative predictor of systolic BP
(SBP), while AUCGLP-1 was not correlated with fasting PG or HbA1c level. In subgroup analyses using the median of AUCGLP-1
to divide the study subjects into high and low GLP-1 response groups, AUCGLP-1 was significantly correlated with both SBP
and diastolic BP (r = 0.40 and 0.28, respectively) in the low GLP-1 response group but not in the high GLP-1 response group.
Conclusions: The results of the present study suggest that GLP-1 secretory function is involved in prevention of BP
elevation and that the GLP-1 response to oral glucose rather increases with aging perhaps as an adaptive phenomenon.
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Introduction
Glucagon-like peptide 1 (GLP-1), one of the incretins, is
secreted from L-cells in the small intestine after meals, contrib-
uting to enhancement of post-prandial insulin secretion, suppres-
sion of glucagon secretion and deceleration of gastric emptying
[1,2]. Both increase in vagal tone and activation of L-cells by
dietary nutrients participate in triggering GLP-1 secretion into the
blood stream. GLP-1 is rapidly inactivated by dipeptidyl
peptidase-4 (DPP-4) and is eliminated mainly from the kidney.
Post-prandial level of GLP-1 is reduced in patients with type 2
diabetes [3,4], and thus DPP-4 inhibitors and GLP-1 analogues
have been widely used for control of plasma glucose (PG) levels in
diabetic patients. However, the physiological functions of GLP-1
in extra-pancreatic tissues have not been fully characterized,
though regulation of bone metabolism, progenitor cell prolifera-
tion in the brain, lipogenesis in adipose tissue and angiogenesis in
the heart have been proposed [1,2]. It is also unclear how basal
(i.e., pre-prandial) GLP-1 level is regulated and how GLP-1
secretory capacity is regulated in healthy subjects.
In the present study, we first examined whether basal (fasting)
GLP-1 level and GLP-1 secretory function are determined by any
of the demographic or metabolic parameters in apparently healthy
subjects who participated in annual health examinations. Second,
we examined the possibility that GLP-1 secretory capacity is
involved in blood pressure (BP) regulation. The rationale for this
hypothesis is two-fold. First, earlier studies [5,6] have demonstrat-
ed that GLP-1 enhances urinary sodium excretion. Second, GLP-1
and its analogues lowered BP in Dahl salt–sensitive rats [7] and in
patients with type 2 diabetes [8–11]. Apparently healthy subjects
in the Tanno-Sobetsu cohort [12,13] were recruited to the present
study, and we examined relationships between fasting plasma
GLP-1 level, plasma GLP-1 response to oral glucose loading, and
demographic and metabolic parameters. Results of the analysis
suggested that endogenous GLP-1 plays a role in BP regulation
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and that GLP-1 response to glucose loading rather increases with
aging perhaps as an adaptive response.
Methods
The protocol of this study was approved by the Ethics
Committee of Sapporo Medical University and we conducted
this study according to the principles expressed in the Declaration
of Helsink. Written informed consent was obtained from all
subjects who participated in the Tanno-Sobetsu Study [12,13].
Study Subjects
We recruited participants in the Tanno-Sobetsu Study [12,13],
a study with a population-based prospective cohort design, to the
present analyses. In the Tanno-Sobetsu Study, residents of two
towns, Tanno and Sobetsu, in Japan were recruited for annual or
biannual medical examination, including standard blood and
urine tests and electrocardiogram. Medical history, including use
of medications, was taken and recorded by registered nurses. Parts
of plasma samples were frozen and stored for later analyses. If the
annual examination showed that fasting PG was 100 , 125 (mg/
dl) and/or glycohemoglobin A1c (HbA1c in national glycohemo-
globin standardization program [NGSP] scale) was 5.6 , 6.4%,
the subject was invited to undergo an oral glucose tolerance test
(OGTT) scheduled one month after the annual examination.
From 2009 , 2011, 881 subjects received annual examinations in
Sobetsu and 315 of them received invitation to OGTT. Totally
128 subjects underwent OGTTs and were recruited to the present
study. They did not differ from subjects who did not respond to
invitation to OGTT (n = 187) in demographic parameters (i.e.,
age, sex, BP, fasting PG, HbA1c, serum lipids and renal function
indices) (data not shown). Based on history taken by the nurses, 25
of 128 subjects were excluded due to clinical diagnosis of diabetes
mellitus and/or regular medications for cardiovascular or meta-
bolic diseases. The remaining 103 subjects constituted the study
population for the present analyses.
Measurements
Medical examinations were performed in the early morning
after an overnight fast. In physical examinations, systolic BP (SBP)
and diastolic BP (DBP) were measured twice after a 5-min rest on
a seat and the values were averaged. Body mass index (BMI, kg/
m2) was calculated as weight (kg)/height2 (meters). Urine was
sampled for determination of albumin and creatinine (Cr) levels.
Peripheral venous blood was drawn for determination of high-
density lipoprotein cholesterol (HDL-C, mg/dL), total cholesterol
(TCHO, mg/dL), fasting PG, triglyceride (TG), serum Cr, high-
sensitivity C-reactive protein (hs-CRP) and brain natriuretic
peptide (BNP). Low-density lipoprotein cholesterol (LDL-C, mg/
dL) was calculated by the Friedewald formula (TCHO - HDL -
TG/5). Estimated glomerular filtration rate (eGFR) was calculated
from data on serum Cr, age and sex by use of equations for
Japanese [14]. HbA1c was determined by using latex coagulation
method and expressed in NGSP scale. OGTT was performed, and
PG, immunoreactive insulin (IRI) and GLP-1 were measured
before and at 60 and 120 min after drinking Trelan-GTM (75 g
glucose in 225 ml water). PG and IRI levels were measured by the
hexokinase method and enzyme immunoassay, respectively. Blood
samples for GLP-1 assay were collected in tubes containing DPP-4
inhibitor (BD P700, Becton, Dickinson and Co.). Plasma intact
GLP-1 level was determined by an ELISA kit (GLP-1 Active
ELISA kit, EGLP-35k, Millipore Inc.), which measures intact
GLP-1 without cross-reacting with the inactive form of GLP-1 (9–
36). As indices of insulin sensitivity, homeostasis model assessment
of insulin resistance (HOMA-IR) and Matsuda-DeFronzo index
were calculated as previously reported [15,16].
Statistical Analysis
Numeric variables are expressed as means 6 SD. Analysis of
variance was used for testing significant differences between group
means. As an index of GLP-1 secretory function, area under the
curve (AUC) of GLP-1 in the OGTT (AUCGLP-1) was calculated
by use of the trapezoidal rule. Similarly, AUCs of PG (AUCPG)
and IRI (AUCIRI) in the OGTT were also calculated. Relation-
ships between parameters were examined by use of simple and
multiple linear regression analyses. In multiple linear regression
analysis, we prepared several models by using all or different
combinations of parameters as independent variables for calcula-
tion of both regression coefficients and Akaike Information
Criterion (AIC). Among the candidate models, we selected the
best-fit model using Akaike’s Information Criterion (AIC) for each
dependent variable. Differences in time courses of PG and IRI in
the OGTT were tested by two-way repeated measures analysis of
variance and Bonferroni post hoc test for multiple comparisons.
Statistical analyses were carried out using JMP (version7 SAS
Institute, Cary, NC, USA). Difference was considered to be
statistically significant if p was less than 0.05.
Results
Demographic Characteristics of Study Subjects
Demographic and clinical parameters in the study subjects are
shown in Table 1. Women had lower SBP and DBP, higher HDL-
C and lower TG level than those in men. While fasting PG and
fasting GLP-1 were comparable in men and women, AUCPG was
smaller and AUCGLP-1 tended to be higher in women than in men.
The other parameters were comparable in men and women.
Of the 103 subjects, 52 subjects (50.5%) had SBP.140 mmHg
and/or DBP.90 mmHg. In the OGTT, impaired glucose
tolerance, impaired fasting PG, and diabetic pattern were
observed in 33, 2 and 2 subjects, respectively. HbA1c levels in
the two subjects showing a diabetic pattern in the OGTT were
5.7% and 6.1%.
Relationships between GLP-1 Secretory Function and
Metabolic Parameters
We first examined whether basal (fasting) GLP-1 level correlates
with age, SBP, DBP, fasting plasma IRI, fasting PG, serum lipids,
HbA1c, HOMA-IR or Matsuda-DeFronzo index. However, none
of the parameters were correlated with basal GLP-1 (Table 2) or
selected as an independent predictor of basal GLP-1 in multiple
linear regression analysis (data not shown).
In univariate linear regression analysis, AUCGLP-1, an index of
secretory function of GLP-1, correlated with BMI and SBP and
tended to correlate with age (Table 2). However, in multiple linear
regression analysis, sex, age and SBP were selected as independent
determinants as shown in Table 3. No significant association was
detected between AUCGLP-1 and HbA1c, fasting TG or choles-
terol levels or eGFR, and addition of any of these parameters to
age, sex and SBP did not improve prediction of AUCGLP-1.
AUCGLP-1 was negatively correlated with AUCPG (r =20.28,
p = 0.004) but not with AUCIRI (r = 0.013, p = 0.896).
In multiple regression analyses for fasting PG level and for
HbA1c level, neither fasting GLP-1 nor AUCGLP-1 was selected as
a significant determinant (data not shown).
GLP-1 Secretory Function and Blood Pressure
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Relationship between BP and GLP-1
Fasting GLP-1 level was not correlated with SBP or DBP
(Table 2). In contrast, AUCGLP-1 was inversely correlated with
SBP (r =20.26, p = 0.0085) as shown in Figure 1, though such a
correlation was not detected for DBP. Table 4 and Table 5 present
results of multiple linear regression analyses for SBP and DBP with
clinical variables. AUCGLP-1 and age were selected as independent
determinants of SBP, though sex was the only variable associated
with DBP in the present dataset. Replacement of fasting IRI with
AUCIRI in Tables 4 and 5 did not improve R
2 values in regression
for SBP or DBP (R2 data not shown).
Subgroup Analyses
To examine possible differences in demographic features
between the subjects with high AUCGLP-1 and those with low
AUCGLP-1, we divided the study subjects into two groups by the
median of AUCGLP-1. As shown in Table 6, the low AUCGLP-1
group was younger, included a larger proportion of men and had
lower baseline GLP-1 level, larger BMI and higher levels of LDL-
C and eGFR than those in the high AUCGLP-1 group. HbA1c and
indices of insulin sensitivities (i.e., Matsuda-DeFronzo index and
HOMA-IR) were not significantly different between the two
groups, though both indices tended to indicate lower insulin
sensitivity in the low AUCGLP-1 group. Interestingly, both SBP and
DBP were significantly correlated with AUCGLP-1 in the low
AUCGLP-1 group (Figure 2), whereas such a correlation was not
detected in the high AUCGLP-1 group.
Time courses of PG and IRI levels during OGTT are shown in
Figure 3. Levels of fasting PG were similar in the two groups
(97.169.9 vs. 96.069.6 mg/dl). However, PG level at 60 min
after oral glucose loading was significantly higher in the low
AUCGLP-1 group than in the high AUCGLP-1 group (170.9647.2
vs. 149.3639.5 mg/dl). In contrast, IRI levels were similar before
and after glucose loading in the high and low AUCGLP-1 groups.
AUCPG was significantly larger in the low AUCGLP-1 group than
Table 1. Demographic and clinical parameters in study
subjects.
All (n = 103) Men (n=43) Women (n=60)
Age (years) 6569 6768 64610
BMI (kg/m2) 24.063.8 24.562.8 23.764.4
SBP (mmHg) 140620 146621 135617*
DBP (mmHg) 79611 83610 76611*
Fasting PG (mg/dl) 96.669.7 97.669.1 95.8610.2
AUCPG (a.u.) 16476335 17736323 15576311*
Fasting IRI (mIU/ml) 6.264.6 6.965.7 5.763.5
AUCIRI (a.u.) 5796397 6296447 5436337
Fasting GLP-1 (pmol/l) 3.3361.81 3.2761.76 3.3761.87
AUCGLP-1 (a.u.) 8926544 7256465 10126568
LDL-C (mg/dl) 131630 130631 131629
HDL-C (mg/dl) 66622 58616 71625*
Triglyceride (mg/dl) 118662 132674 107650*
HbA1c (%) 5.760.2 5.760.2 5.760.2
S-Cr (mg/dl) 0.7160.14 0.8160.14 0.6360.09*
eGFR (mL/min/1.73 m2) 72.2612.5 72.7613.9 71.9611.5
U-Alb/U-Cr (mg/gCr) 17.0654.2 25.8684.3 11.068.6
BNP (pg/ml) 20.9616.4 17.6615.9 23.3616.5
hs-CRP (mg/dl) 0.0860.10 0.1060.12 0.0760.09
Matsuda-DeFronzo index 8.164.6 7.564.9 8.564.3
HOMA-IR 1.561.2 1.761.5 1.460.9
HOMA-b 67.5643.3 71.4649.6 64.7638.3
Data are presented as means 6 SD.
*p,0.05 vs. Men.
SBP, systolic blood pressure; DBP, diastolic blood pressure; PG, plasma glucose;
IRI, immunoreactive insulin; AUCGLP-1, area under the curve of GLP-1 level
during 75 g oral glucose tolerance test; S-Cr, serum creatinine; U-Alb/U-Cr,
urinary albumin concentration-to-urinary creatinine concentration ratio; hs-CRP,
high-sensitivity C-reactive protein; a.u., arbitrary unit.
doi:10.1371/journal.pone.0067578.t001
Table 2. Univariate linear regression analyses for fasting GLP-
1 level and AUCGLP-1.
Fasting GLP-1
(pmol/L) AUCGLP-1
r p r p
Age (years) 20.068 0.49 0.18 0.073
BMI (kg/m2) 20.13 0.20 20.23 0.017
SBP (mmHg) 20.15 0.13 20.26 0.0085
DBP (mmHg) 0.029 0.77 20.15 0.13
Fasting PG (mg/dl) 20.025 0.80 20.049 0.62
Fasting IRI (mIU/ml) 0.024 0.81 20.12 0.22
LDL-C (mg/dl) 20.082 0.41 20.14 0.15
HDL-C (mg/dl) 20.036 0.71 0.16 0.12
Triglyceride (mg/dl) 20.027 0.79 20.042 0.68
HbA1c (%) 0.12 0.24 0.15 0.13
S-Cr (mg/dl) 20.092 0.36 20.091 0.36
eGFR (ml/min/1.73 m2) 0.096 0.34 20.16 0.11
U-Alb/U-Cr (mg/gCr) 20.076 0.45 20.13 0.21
BNP (pg/ml) 20.17 0.087 0.14 0.17
hs-CRP (mg/dl) 0.020 0.95 20.041 0.68
Matsuda-DeFronzo index 20.077 0.44 0.020 0.84
HOMA-IR 0.020 0.84 20.12 0.23
HOMA-b 0.018 0.86 20.12 0.24
SBP, systolic blood pressure; DBP, diastolic blood pressure; PG, plasma glucose;
IRI, immunoreactive insulin; AUCGLP-1, area under the curve of GLP-1 level
during 75 g oral glucose tolerance test; S-Cr, serum creatinine; U-Alb/U-Cr,
urinary albumin concentration-to-urinary creatinine concentration ratio; hs-CRP,
high-sensitivity C-reactive protein; a.u., arbitrary unit.
doi:10.1371/journal.pone.0067578.t002
Table 3. Multiple linear regression analysis for AUCGLP-1 and
independent variables.
B SE b t p
Sex 118.0 53.1 0.215 2.22 0.029
Age (years) 12.82 6.18 0.217 2.08 0.041
BMI (kg/m2) 221.39 13.4 20.150 21.60 0.113
SBP (mmHg) 26.221 2.66 20.226 22.34 0.022
eGFR (ml/min/1.73 m2) 21.814 4.36 20.042 20.42 0.679
B, partial regression coefficient; SE, standard error; b, standardized partial
regression coefficient.
The square of the coefficient of multiple correlation (R2) in this model = 0.19.
doi:10.1371/journal.pone.0067578.t003
GLP-1 Secretory Function and Blood Pressure
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in the high AUCGLP-1 group, though AUCIRI values were similar
in the two groups (Table 6).
Discussion
Determinants of Baseline Plasma GLP-1 Level and GLP-1
Secretory Function
Since GLP-1 has extra-pancreatic targets of actions [1,2], not
only post-prandial but also baseline (fasting) level of GLP-1
potentially influence functions of extra-pancreatic tissues. Howev-
er, a few studies have provided information on factors regulating
baseline plasma GLP-1 level. Jørgensen et al. [17] reported that
growth hormone deficiency induced an increase in fasting GLP-1
level. Pannacciulli et al. [18] showed that fasting GLP-1 level was
positively correlated with rates of energy expenditure and
negatively correlated with respiratory quotient, indicating a
possible link between fatty acid oxidation and GLP-1 level. Since
the level of daily energy expenditure potentially modifies insulin
sensitivity, we assumed that insulin sensitivity indexes or lipid
levels correlate with GLP-1 level. However, we did not find a
significant correlation of baseline GLP-1 level with Matsuda-
DeFronzo index, HOMA-IR, serum TG, or HDL-C. Also, no
significant correlation was found between baseline GLP-1 and
BMI, being consistent with results of earlier studies showing that
fasting GLP-1 level in obese subjects was unchanged after weight
reduction [19,20]. In contrast to fasting GLP-1 level, post-prandial
GLP-1 level was reduced after weight loss in a study by Adam
et al. [19]. Nevertheless, the present observations indicate that
insulin sensitivity or BMI are not contributory to physiological
regulation of fasting GLP-1 level.
To our knowledge, there has been no study that systematically
examined determinants of GLP-1 secretory function in non-
diabetic subjects. Using AUCGLP-1 during OGTT, we examined
the associations of GLP-1 secretory function with metabolic
parameters and found that sex and age are independent
determinants of AUCGLP-1 (Table 3). The results indicate that
response of GLP-1 secretion to glucose loading is larger in women
than in men. However, in an earlier study by Carroll et al. [21],
Figure 1. Relationship between blood pressure and AUCGLP-1. AUCGLP-1 was weakly correlated with SBP (r =20.26, p = 0.0085, Panel A).
However, a significant correlation was not observed for the AUCGLP-1– DBP relationship (Panel B). SBP, systolic blood pressure; DBP, diastolic blood
pressure; AUCGLP-1, area under the curve of GLP-1 level in the oral glucose tolerance test.
doi:10.1371/journal.pone.0067578.g001
Table 4. Multiple linear regression analysis for SBP and
independent variables.
B SE b t p
Sex 23.26 2.01 20.164 21.62 0.108
Age (years) 0.500 0.240 0.233 2.08 0.040
BMI (kg/m2) 0.0383 0.568 0.00738 0.067 0.946
AUCGLP-1 (a.u.) 20.00868 0.00366 20.239 22.37 0.020
Fasting IRI (mU/ml) 0.518 0.468 0.120 1.11 0.270
eGFR (ml/min/1.73 m2) 0.0124 0.166 0.00801 0.074 0.941
B, partial regression coefficient; SE, standard error; b, standardized partial
regression coefficient; a.u., arbitrary unit.
The square of the coefficient of multiple correlation (R2) in this model = 0.17.
doi:10.1371/journal.pone.0067578.t004
Table 5. Multiple linear regression analysis for DBP and
independent variables.
B SE b t p
Sex 23.20 1.19 20.279 22.70 0.008
Age (years) 20.0644 0.142 20.0523 20.455 0.650
BMI (kg/m2) 0.194 0.335 0.0652 0.579 0.564
AUCGLP-1 (a.u.) 20.0007670.00216 20.0368 20.355 0.723
Fasting IRI (mU/ml) 0.242 0.276 0.0972 0.876 0.383
eGFR (ml/min/1.73 m2) 0.0309 0.0982 0.0348 0.315 0.754
B, partial regression coefficient; SE, standard error; b, standardized partial
regression coefficient; a.u., arbitrary unit.
The square of the coefficient of multiple correlation (R2) in this model = 0.12.
doi:10.1371/journal.pone.0067578.t005
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time courses of GLP-1 during a 60-min postprandial period were
similar in men and women. The number of subjects in their study
was small (19 men and 20 women) and they used a 510 kcal test
meal to evoke responses of GLP-1 and other hormones. Thus,
absence of a sex difference in GLP-1 secretory function in the
study by Carroll et al. [21] might have been a type II error or the
sex difference in GLP-1 response in the present study might be
specific to the situation of loading glucose only. This issue needs
further investigation.
In contrast to our expectation, age was indicated to be a positive
predictor of AUCGLP-1 in the present analysis (Table 3). We have
no clear explanation for the mechanism underlying the positive
age-AUCGLP-1 relationship. Since neither serum Cr nor eGFR
was selected as an independent determinant of AUCGLP-1 in
multiple linear regression analysis (Table 3), age-related decline in
renal clearance of GLP-1 cannot explain the age-AUCGLP-1
relationship. One possible explanation is slower degradation of
GLP-1 by DPP-4 in elderly subjects. However, this possibility is
not supported by recent observations [22–24]. Korosi et al. [22]
and Tahara et al. [23] showed that plasma DPP-4 activities were
similar in young and elderly subjects. Damholt et al. [24] reported
that plasma half-life of intravenously injected liraglutide, a GLP-1
analogue, was similar in young and elderly subjects, indicating
comparable levels of DPP-4 activity in the two age groups.
Another possible explanation for higher AUCGLP-1 in elderly
subjects is the age-dependent increase in sensitivity of L-cells to
glucose. However, that possibility is counterintuitive and currently
lacks any supporting evidence.
GLP-1 Secretory Function and PG Level after Glucose
Loading
We could not find a significant relationship between AUCGLP-1
and HbA1c in the present study subjects, 32% of whom showed
impaired glucose tolerance. However, as shown in Figure 3, PG
levels after glucose loading were higher in the low AUCGLP-1
group than in the high AUCGLP-1 groups. On the other hand, time
courses of IRI during the OGTT were similar in the two groups,
indicating that insulin sensitivity was reduced in association with
decrease in GLP-1 secretory capacity. Two indices of insulin
sensitivity (Matsuda-DeFronzo index and HOMA-IR) tended to
show lower insulin sensitivity in the low AUCGLP-1 group (Table 6),
though the differences did not reach statistical significance.
Furthermore, an association of insulin resistance and reduced
response of plasma GLP-1 level to glucose loading has been
Figure 2. Blood pressure - AUCGLP-1 relationships in the high and low AUCGLP-1 groups. In the high AUCGLP-1 group, neither SBP nor DBP
correlated with AUCGLP-1 (Panels A and B). In contrast, there were significant correlations between AUCGLP-1 and SBP (r =20.40, p = 0.0032, Panel C)
and between AUCGLP-1 and DBP (r =20.28 p = 0.0448, Panel D) in the low AUCGLP-1 group. SBP, systolic blood pressure; DBP, diastolic blood pressure;
AUCGLP-1, area under the curve of GLP-1 level in the oral glucose tolerance test.
doi:10.1371/journal.pone.0067578.g002
GLP-1 Secretory Function and Blood Pressure
PLOS ONE | www.plosone.org 5 July 2013 | Volume 8 | Issue 7 | e67578
observed in subjects with type 2 diabetes as well [3,4]. Taken
together, the present results indicate that reduced GLP-1 secretory
function is associated with insulin resistance and post-prandial
hyperglycemia even before insulin secretion is compromised.
The reason for the association between reduced GLP-1
secretion and insulin resistance is unclear. It is unlikely that
change in plasma somatostatin level is involved in the association.
Somatostatin, which suppresses GLP-1 secretion, was reported to
be reduced in obese subjects [25] and in a rat model of metabolic
syndrome [26]. In contrast, insulin has been shown to enhance
GLP-1 secretion in an ERK-dependent manner, and this response
of GLP-1 to insulin was attenuated by chronic hyperinsulinemia in
human NCI-H716L cells and mouse models in vitro and in vivo
[27]. Thus, there is the possibility that chronic hyperinsulinemia
mediates association of insulin resistance and reduction in GLP-1
secretion in diabetic patients. However, in the present study
subjects, in whom fasting IRI levels were mostly within the normal
range, a significant correlation between fasting IRI and AUCGLP-1
was not detected (Table 2).
Relationship between Endogenous GLP-1 and BP
GLP-1 has extra-pancreatic actions relevant to BP regulation
[1,2,28–30]. The GLP-1 receptor has been shown to localize in
endothelial cells and vascular smooth muscle cells [1,2], and
activation of the GLP-1 receptor induces nitric oxide production
in endothelial cells and suppresses proliferation of vascular smooth
muscle cells [28–30]. GLP-1 is also involved in sodium handling in
the kidney. Gutzwiller et al. [5,6] showed that GLP-1 increased
sodium excretion in the proximal renal tubule in both healthy
subjects and obese insulin-resistant subjects. Such a natriuretic
action of a GLP-1 receptor agonist was not detected in GLP-1
receptor knockout mice [31]. BP tended to be higher in the GLP-1
receptor knockout mice than in wild-type mice, though the
difference was not statistically significant. Furthermore, a recent
study by Kim et al. [32] showed that activation of the GLP-1
receptor in the atria promotes secretion of atrial natriuretic
peptide, leading to blood pressure reduction in mice. Collectively,
the findings support the notion that the GLP-1 receptor in the
vasculature, kidney and atria participates in BP regulation.
Consistent with the vasoprotective actions of GLP-1, GLP-1
infusion has been reported to improve flow-mediated vasodilata-
tion in patients with type 2 diabetes [33]. In addition, Tesauro
et al. [34] recently reported that loss of insulin-mediated
enhancement of endothelial-dependent and -independent vasodi-
lation in patients with metabolic syndrome was restored by
infusion of GLP-1. This effect of GLP-1 was mimicked by vitamin
C and the combination of GLP-1 and vitamin C did not further
improve vasodilatory response, suggesting that the pathologic
mechanism of reactive oxygen species production is a target of
GLP-1. Furthermore, GLP-1 analogues and DPP-4 inhibitors
Table 6. Demographic and clinical parameters in low AUCGLP-1 group and high AUCGLP-1 group.
Low AUCGLP-1 Group (n=51) High AUCGLP-1 Group (n=52)
Men, n (%) 30 (59)* 13 (25)
Age (year) 63610* 6768
BMI (kg/m2) 25.563.9* 22.663.1
SBP (mmHg) 146620* 134618
DBP (mmHg) 82612* 76611
Fasting PG (mg/dl) 97.169.9 96.069.6
AUCPG (a.u.) 17366359* 15616286
Fasting IRI (mIU/ml) 7.065.6 5.563.0
AUCIRI (a.u.) 6166450 5426338
Fasting GLP-1 (pmol/l) 2.7560.76* 3.8962.32
AUCGLP-1 (a.u.) 5126112* 12656541
LDL-C (mg/dl) 139628* 123629
HDL-C (mg/dl) 62615 69627
Triglyceride (mg/dl) 118655 117670
HbA1c (%) 5.760.2 5.760.2
S-Cr (mg/dl) 0.7260.15 0.7060.14
eGFR (mL/min/1.73 m2) 75.3613.7* 69.2610.5
U-Alb/U-Cr (mg/gCr) 25.6677.0 8.8167.2
BNP (pg/ml) 17.8612.3 23.9619.4
hs-CRP (mg/dl) 0.1060.11 0.0760.09
Matsuda-DeFronzo index 7.965.2 8.363.9
HOMA-IR 1.761.5 1.360.8
HOMA-b 74.2652.3 60.9631.3
Data are presented as mean 6 SD.
*p,0.05 vs. High AUCGLP-1 Group.
SBP, systolic blood pressure; DBP, diastolic blood pressure; PG, plasma glucose; IRI, immunoreactive insulin; AUCGLP-1, area under the curve of GLP-1 level during 75 g
oral glucose tolerance test; S-Cr, serum creatinine; U-Alb/U-Cr, urinary albumin concentration-to-urinary creatinine concentration ratio; hs-CRP, high-sensitivity C-
reactive protein; a.u., arbitrary unit.
doi:10.1371/journal.pone.0067578.t006
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have been shown to reduce BP (prior to reduction of body weight)
in diabetic and non-diabetic patients with hypertension, [2,8–
11,35]. In contrast to hypertensive subjects, normotensive subjects
have been reported to be insensitive to the BP-lowering effect of
GLP-1 [33,36,37]. GLP-1 infusion did not significantly change BP
or heart rate unless hypoglycemia was induced [33,36,37].
However, the present study showed that an index of GLP-1
secretory function, AUCGLP-1, negatively correlated with SBP
(Figure 1) and the association of AUCGLP-1 with SBP was
independent of BMI, plasma IRI and age (Table 3 and Table 4).
Furthermore, the relationship between BP and AUCGLP-1 was
clearer in the group with low AUCGLP-1 (Figure 2). Taken
together, the findings suggest that a slight decline in GLP-1
secretory function allows BP to elevate. In other words, preserved
GLP-1 secretory function, leading to physiological GLP-1-
mediated vasodilatation and natriuresis, may play a role in
prevention of BP elevation.
Acute administration of GLP-1 or a GLP-1 analogue, exenatide,
does not decrease BP in healthy subjects [36,38]. Thus, the inverse
correlation between AUCGLP-1 and SBP (Figures 1 and 2) is
unlikely to be mediated by acute effects of GLP-1 on the
vasculature and/or the sympathetic nervous system and perhaps
reflects chronic vasoprotective and natriuretic actions of endoge-
nous GLP-1 [39–41].
Level of daily sodium intake is an established determinant of BP,
and our recent study confirmed that estimated sodium intake
correlated with BP in subjects in the Tanno-Sobetsu cohort [42].
Sodium intake levels estimated from sex, body weight, urinary
sodium and Cr data by use of the equation for Japanese [43] were
13.663.8 g/day in men and 12.563.5 g/day in women in this
cohort. It would have been interesting if natriuresis could have
been assessed for examination of the relationship between level of
natriuresis and AUCGLP-1. However, it is not clear whether
estimated sodium intake is sensitive enough for analysis of a
modest change in natriuresis by its regulatory factors, and
collection of 24-h urine samples from a general population is
difficult. Thus, we did not attempt to directly examine relationship
between natriuresis and AUCGLP-1 in the present study.
Limitations in the Present Study
There are several limitations in this study. First, subjects in the
Tanno-Sobetsu cohort received OGTT on a voluntary basis in
addition to examinations mandatory for registration, and invita-
tion to undergo an OGTT was based on FPG and HbA1c data
indicating possible glucose intolerance. Thus, selection bias for
both higher health-oriented subjects and those with lower glucose
tolerance is likely to be present in this study. Second, we excluded
all subjects on regular medications and aimed to exclude patients
with untreated diabetes and cardiac diseases primarily by medical
history (i.e., questionnaire). Thus, the possibility of asymptomatic
and undiagnosed cardiovascular diseases could not be ruled out. In
fact, BP was above normal limits in approximately half of the study
subjects, though diagnosis of hypertension cannot be made by a
single measurement of BP. Third, the present study has limitations
due to observational cross-sectional analysis and we could not
critically discuss cause-and-results relationships for significant
associations of AUCGLP-1 with age and with BP. Longitudinal
analyses are necessary to confirm the present findings, particularly
age-related change in GLP-1 secretory function and relationship
between BP and GLP-1 secretory function.
Conclusion
Multiple linear regression analyses of data from subjects on no
medication in a general population indicated that an index of
GLP-1 secretory function, AUCGLP-1, positively correlated with
age and negatively correlated with SBP. Endogenous GLP-1 may
be involved in BP regulation, and age-dependent increase in GLP-
1 secretory response to glucose loading might be an adaptive
Figure 3. Time courses of PG and IRI in the OGTT. Broken lines and solid lines indicate the low AUCGLP-1 group and high AUCGLP-1 group,
respectively. The low AUCGLP-1 group showed significantly higher PG level at 60 min after glucose loading than in the high AUCGLP-1 group (Panel A).
*p = 0.039. There was no inter-group difference in time courses of plasma IRI during the OGTT (Panel B). PG, plasma glucose; IRI, immunoreactive
insulin.
doi:10.1371/journal.pone.0067578.g003
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response. Mechanisms underlying the changes in AUCGLP-1 and
the relationship between endogenous GLP-1 and BP regulation
remain to be further studied.
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